Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

ABSTRACT:

Purpose

Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear. We therefore examined this question using a national cohort.

Methods

 The National Cancer Database was queried for patients histopathologically diagnosed with gliosarcoma between 2010 and 2019. The associations between MGMT promoter methylation, first-line single-agent chemotherapy-presumed to be temozolomide herein-and overall survival (OS) were examined using log-rank tests and Cox regression, with correction for multiple testing (p < 0.01 was significant).

Results

580 newly-diagnosed gliosarcoma patients with MGMT status were available, among whom 33.6% were MGMT promoter methylated. Median OS for gliosar

SUBMITTER: Kavouridis VK 

PROVIDER: S-EPMC10276926 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature